SS-31
2S10 · 10mg · 2026-10-21 · N/A
COA PDF ↗
2S5Images are illustrative. Actual specifications are as selected and confirmed in writing.
Longevity & Mitochondrial Research
Mitochondrial function, muscle capacity and fatigue
SS-31 specifications and reference prices. Select a specification to add it to your cart.
For laboratory research only. Not for human or veterinary use.
2S10 · 10mg · 2026-10-21 · N/A
COA PDF ↗| SKU | Specification / pack | Reference price (USD) |
|---|---|---|
| 2S5 | 5mg/vial x 10vials | US$105.88 |
| 2S10 | 10mg/vial x 10vials | US$200 |
| 2S50 | 50mg/vial x 10vials | US$564.71 |
Temporarily sold-out specifications can still be added to an inquiry to ask about restocking. An inquiry is not an order or an agreed price.
Explore Longevity & Mitochondrial Research ↗ · View all products
This page organizes directly related information on SS-31 regarding mitochondrial function, muscle performance, and fatigue. First, look at research questions and findings, then verify the population or species, study formulations, and scope of interpretation.
The following presents common research-context references for reconstitution, storage, dosage and cycles. The following presents common references in research settings. This page does not constitute advice for use in humans or animals.
| Purpose / Setting | Common Reference |
|---|---|
| Explanation | Mitochondrial protection, injection study |
Note: The above describes common research-context references, rather than clinical recommendations. Refer to the batch COA and research protocol. For research use only; not for human or animal use.
Improves overall skeletal muscle and some single-fiber contraction indicators. Additionally, research reports: improves muscle anti-fatigue capacity and some cardiac functions, and slows the accumulation of frailty.[1] ↗ [2] ↗
Improves overall skeletal muscle and some single-fiber contraction indicators.[1] ↗
HFpEF rats; 12-week intervention
Disease animal models cannot be extrapolated to improved exercise performance in healthy humans.
Circulation. Heart failure · Volume and issue year 2026
First published 2026-06-15 · PMID 42290373
DOI 10.1161/CIRCHEARTFAILURE.126.014397
Improves muscle anti-fatigue capacity and some cardiac functions, and slows the accumulation of frailty.[2] ↗
Aged C57BL/6J mice; 8-week elamipretide treatment
No significant reversal of epigenetic or transcriptional age was detected; cannot promote reversing biological age; not equivalent to effects in healthy humans.
Aging Cell · Volume and Year 2025
First published 2025-03-13 · PMID 40080911
DOI 10.1111/acel.70026
Walking distance, fatigue, and some cardiac indicators improved relative to the baseline of the open-label extension period.[3] ↗
Barth syndrome patients; TAZPOWER up to 168 weeks open-label extension
Only 10 patients entered the extension phase, while 8 completed it; There was no placebo comparison during the extension period, and fatigue resistance was not extrapolated to ordinary people.
Genetics in Medicine: official journal of the American College of Medical Genetics · Volume, Issue, Year 2024
First published 2024-04-08 · PMID 38602181
DOI 10.1016/j.gim.2024.101138
Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
Compare study populations, findings and scope.
Improves overall skeletal muscle and some single-fiber contraction indicators. Additionally, research reports: improves muscle anti-fatigue capacity and some cardiac functions, and slows the accumulation of frailty.[1] ↗ [2] ↗
Human long-term data from small Barth syndrome population; other muscle performance studies included aged mice and disease rats. Cannot promise anti-fatigue effects in general healthy people based on this.[3] ↗ [2] ↗ [1] ↗
HFpEF rats; 12-week intervention; aged C57BL/6J mice; 8-week elamipretide treatment; Barth syndrome patients; TAZPOWER maximum 168-week open-label extension. Disease animal models cannot be extrapolated to improved exercise performance in healthy humans.[1] ↗ [2] ↗ [3] ↗
VENTRO PEPTIDES & BIOTECH · RESEARCH PRODUCT RETAIL
Compare specifications, reference prices and COA reports. Add products to your cart to request a quote.
01 / CATALOG
Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
10mg/vial x 10vials
US$90.91Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
20mg/vial x 10vials
US$160.61Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
10mg/vial x 10vials
US$109.09Images are illustrative. Actual specifications are as selected and confirmed in writing.
Repair & Recovery Research
10mg/vial x 10vials
US$133.33Images are illustrative. Actual specifications are as selected and confirmed in writing.
Longevity & Mitochondrial Research
20mg/vial x 10vials
US$257.58Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
10mg*10vials
US$164.71Images are illustrative. Actual specifications are as selected and confirmed in writing.
Growth Hormone & IGF-1
1mg/vial x 10vials
US$505.8802 / DISCOVER
03 / ABOUT VENTRO
Ventro supports research product retail purchases with clear pack specifications, available quality documents, and responsive international support.
04 / QUALITY SYSTEM
Browse the available COA reports by product. Confirm documentation for your order with our team.
RESEARCH PRODUCT INQUIRY
Tell us the product, specification, and expected quantity. Our team will respond with pricing and available documents.